Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAB008 vs bevacizumab plus paclitaxel/carboplatin in non-squamous NSCLC
CTR20170244Phase 3Completed
- Sponsor
- Tianjin Pharmaceutical Holdings
- Start
- May 2017
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of pusintin in non-small cell lung cancer (NSCLC), sponsored by Tianjin Pharmaceutical Holdings. Started May 2017; status: completed.
02
Drugs
pusintin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20170244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20170244.